Concourse Financial Group Securities’s Oramed Pharmaceuticals ORMP Stock Holding History

Concourse Financial Group Securities’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$2.31K	–	1444
2024 Q4	$2.31K	Hold	1,000	–	–	﹤0.01%	1997
2024 Q3	$2.44K	Hold	1,000	–	–	﹤0.01%	1970
2024 Q2	$2.57K	Hold	1,000	–	–	﹤0.01%	1997
2024 Q1	$2.92K	Hold	1,000	–	–	﹤0.01%	1993
2023 Q4	$2.31K	Hold	1,000	–	–	﹤0.01%	1997
2023 Q3	$2.61K	Hold	1,000	–	–	﹤0.01%	1953
2023 Q2	$3.58K	Hold	1,000	–	–	﹤0.01%	1907
2023 Q1	$2.18K	Hold	1,000	–	–	﹤0.01%	2043
2022 Q4	$12K	Hold	1,000	–	–	﹤0.01%	1598
2022 Q3	$6K	Hold	1,000	–	–	﹤0.01%	1614
2022 Q2	$5K	Hold	1,000	–	–	﹤0.01%	1847
2022 Q1	$9K	Hold	1,000	–	–	﹤0.01%	1720
2021 Q4	$14K	Hold	1,000	–	–	﹤0.01%	1768
2021 Q3	$22K	Buy	+1,000	New	+$17K	﹤0.01%	1633

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Concourse Financial Group Securities's ORMP Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Oramed Pharmaceuticals (ORMP) in Q1 2025, closing a stake of 1,000 shares — an estimated $2.31K sold.

Concourse Financial Group Securities first reported a position in ORMP in Q3 2021 and held it in 14 quarters. The position peaked at $22K in Q3 2021. 52 funds tracked by Wall St. Rank hold ORMP as of Q1 2025.

Concourse Financial Group Securities reported no remaining Oramed Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Concourse Financial Group Securities sold 1,000 Oramed Pharmaceuticals shares in Q1 2025, an estimated $2.31K.
Concourse Financial Group Securities first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 14 quarters.
Concourse Financial Group Securities's Oramed Pharmaceuticals position peaked at $22K in Q3 2021.
52 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.